Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies - PubMed
3 months ago
- #Biomarkers
- #Triple-negative breast cancer
- #Targeted therapy
- Triple-negative breast cancer (TNBC) is highly heterogeneous and aggressive, lacking biomarkers and targeted therapies.
- Researchers identified basal identity genes to refine TNBC subclassification, leading to the discovery of true basal TNBC (tB-TNBC), linked to poorer prognosis.
- High-throughput screening identified dasatinib as a promising treatment for tB-TNBC, showing efficacy in patient-derived xenograft models.
- TAGLN was found to be a predictive biomarker for dasatinib response, influencing drug sensitivity.
- The study supports using basal markers for TNBC stratification and highlights dasatinib as a targeted therapy for tB-TNBC patients.